Collinet Pierre, Vereecque Rodolphe, Sabban Frédéric, Vinatier Denis, Leblanc Eric, Narducci Frabrice, Querleu Denis, Quesnel Bruno
Hôpital Jeanne de Flandre, Clinique de Gynécologie-Obstétrique CHRU Lille, Lille Cedex, France.
J Obstet Gynaecol Res. 2006 Oct;32(5):449-53. doi: 10.1111/j.1447-0756.2006.00435.x.
Abnormalities in the p53 and p16 tumor suppressor genes are one of the most common occurrences associated with human neoplasia. Consequently, restoration of wild-type p53 or p16 functions is seen as a particularly promising approach for cancer gene therapy. In vitro and in vivo data have demonstrated that virus-mediated p53 gene transfer can induce active cell death and ovarian tumor regression.
To evaluate the efficiency of intratumoral injection of naked DNA in tumor growth inhibition in an ovarian xenograft model. For that purpose, plasmid vectors encoding wild-type p53 (wt-p53) or p16 alone or in combination were used.
Nude mice were injected subcutaneously with the human ovarian adenocarcinoma cell line SKOV3. Three weeks after xenograft, tumor-bearing mice were injected twice a week with plasmid vectors carrying WT-p53 and/or WT-p16 cDNA. Empty plasmids and saline buffer were used as control. Tumor growth was monitored to evaluate the inhibition potential with p53 and/or p16 restoration.
When compared to the control, intratumoral repeated injections of naked plasmid DNA encoding wt-p53 were inhibiting tumor growth. This inhibition was not observed with p16 and no synergy could be obtained between p53 and p16. p53 expression was restored in 84% of mice injected with plasmid encoding wt-p53. p16 expression was restored in 63% of mice injected with plasmid encoding p16.
In this report we demonstrated that: (i) naked DNA represents an efficient gene transfer in the SKOV3 xenograft model; (ii) restoration of wt-p53 gene allows tumor growth inhibition; and (iii) this inhibition could be correlated with p53 expression as seen in 84% of treated mice after repeated naked DNA injections. These results allow us to envisage naked DNA as a therapeutic adjuvant in ovarian cancer treatment, concomitantly with tumor resection and chemotherapy.
p53和p16肿瘤抑制基因异常是人类肿瘤最常见的现象之一。因此,恢复野生型p53或p16功能被视为癌症基因治疗中一种特别有前景的方法。体外和体内数据表明,病毒介导的p53基因转移可诱导细胞主动死亡和卵巢肿瘤消退。
评估裸DNA瘤内注射对卵巢异种移植模型肿瘤生长的抑制效率。为此,使用了单独或联合编码野生型p53(wt-p53)或p16的质粒载体。
将人卵巢腺癌细胞系SKOV3皮下注射到裸鼠体内。异种移植三周后,给荷瘤小鼠每周注射两次携带WT-p53和/或WT-p16 cDNA的质粒载体。空质粒和生理盐水缓冲液用作对照。监测肿瘤生长以评估p53和/或p16恢复后的抑制潜力。
与对照组相比,瘤内重复注射编码wt-p53的裸质粒DNA可抑制肿瘤生长。p16未观察到这种抑制作用,p53和p16之间也未获得协同作用。在注射编码wt-p53质粒的小鼠中,84%恢复了p53表达。在注射编码p16质粒的小鼠中,63%恢复了p16表达。
在本报告中,我们证明:(i)裸DNA在SKOV3异种移植模型中是一种有效的基因转移方式;(ii)野生型p53基因的恢复可抑制肿瘤生长;(iii)这种抑制作用可能与p53表达相关,如在重复裸DNA注射后84%的治疗小鼠中所见。这些结果使我们能够设想裸DNA作为卵巢癌治疗中的一种治疗辅助手段,与肿瘤切除和化疗同时使用。